Chimerix Inc. (NASDAQ:CMRX) traded up 2.4% during mid-day trading on Friday . The company traded as high as $3.91 and last traded at $3.90, with a volume of 254,053 shares. The stock had previously closed at $3.81.

A number of equities research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Chimerix from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a research report on Wednesday, May 11th. FBR & Co reiterated a “hold” rating on shares of Chimerix in a research report on Tuesday, May 10th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $16.98.

The stock’s 50-day moving average price is $4.13 and its 200-day moving average price is $5.64. The stock’s market cap is $185.78 million.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.66) by $0.09. The firm had revenue of $1.20 million for the quarter, compared to analyst estimates of $2.79 million. Equities research analysts anticipate that Chimerix Inc. will post ($2.06) earnings per share for the current fiscal year.

In related news, Director Ernest Mario purchased 50,000 shares of the business’s stock in a transaction on Friday, June 24th. The shares were purchased at an average price of $3.70 per share, with a total value of $185,000.00. Following the completion of the purchase, the director now owns 381,440 shares in the company, valued at approximately $1,411,328. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO M Michelle Berrey purchased 13,188 shares of the business’s stock in a transaction on Friday, June 24th. The stock was bought at an average cost of $3.69 per share, for a total transaction of $48,663.72. Following the purchase, the chief executive officer now owns 258,821 shares of the company’s stock, valued at approximately $955,049.49. The disclosure for this purchase can be found here.

A number of hedge funds and institutional investors recently made changes to their positions in CMRX. Morgan Stanley raised its position in shares of Chimerix by 96.7% in the fourth quarter. Morgan Stanley now owns 187,163 shares of the biopharmaceutical company’s stock worth $1,674,000 after buying an additional 92,005 shares during the last quarter. Trexquant Investment LP raised its position in shares of Chimerix by 453.5% in the fourth quarter. Trexquant Investment LP now owns 131,184 shares of the biopharmaceutical company’s stock worth $1,174,000 after buying an additional 107,484 shares during the last quarter. Finally, Jennison Associates LLC raised its position in shares of Chimerix by 67.9% in the fourth quarter. Jennison Associates LLC now owns 1,273,779 shares of the biopharmaceutical company’s stock worth $11,400,000 after buying an additional 515,029 shares during the last quarter.

Chimerix, Inc a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Company’s lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.